Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.

Abstract

PURPOSE:

To describe two cases of neovascular age-related macular degeneration (AMD) that progressed despite a single intravitreal injection of pegaptanib sodium (Macugen) six weeks earlier.

DESIGN:

Interventional case report.

METHODS:

A 62-year-old man and a 76-year-old woman with occult and minimally classic lesions, respectively, each received a single injection of intravitreal pegaptanib.

RESULTS:

Within six weeks of an intravitreal pegaptanib injection, the choroidal neovascularization (CNV) progressed. In one eye, the chronic occult lesion developed subfoveal classic CNV. In the other eye, the classic component of the minimally classic lesion tripled in size.

CONCLUSIONS:

A single dose of intravitreal pegaptanib was not effective in these two patients at six weeks. This report reminds the ophthalmologist to consider obtaining a fluorescein angiogram during follow-up after an intravitreal pegaptanib injection to monitor CNV lesion characteristics, particularly if the visual acuity decreases.

• Authors: Adrienne J Williams, Sharon Fekrat
• Journal: American journal of ophthalmology (Am J Ophthalmol) Vol. 142 Issue 4 Pg. 683-4 (Oct 2006) ISSN: 0002-9394 [Print] United States
• PMID: 17011868 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Aptamers, Nucleotide
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• pegaptanib

Topics

• Aged
• Angiogenesis Inhibitors (administration & dosage)
• Aptamers, Nucleotide (administration & dosage)
• Choroidal Neovascularization (drug therapy, physiopathology)
• Disease Progression
• Female
• Fluorescein Angiography
• Humans
• Injections
• Macular Degeneration (drug therapy, physiopathology)
• Male
• Middle Aged
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Vitreous Body